[6-K] Nanobiotix S.A. American Current Report (Foreign Issuer)
Citigroup Global Markets Holdings Inc., guaranteed by Citigroup Inc., is offering 13-month Autocallable Contingent Coupon Securities linked to Freeport-McMoRan Inc. (FCX). Each $1,000 security pays a monthly contingent coupon of at least 12.30% p.a. provided FCX’s closing price on the valuation date is at or above the Coupon Barrier (69% of the initial value). If, on any monthly Autocall Date beginning after six months, FCX closes at or above its initial value, the notes are automatically redeemed at par plus the coupon.
Principal at risk: If the notes are not autocalled and FCX closes below the Final Barrier (69% of initial) on the final valuation date, investors receive a fixed number of FCX shares (or cash equivalent) based on the equity ratio, potentially worth far less than $1,000 and as little as zero. Hypothetical payouts illustrate full redemption down to a �31% underlying return and steep losses below �31.01%.
Key terms:
- Pricing date: 10-Jul-2025; Maturity: 13-Aug-2026
- Monthly valuation & coupon observation; same dates double as potential autocalldates after month 6
- No market listing; secondary liquidity uncertain
- Credit exposure to Citigroup Global Markets Holdings Inc. and the Citigroup Inc. guarantee
Principal risks: up to 100% loss of invested amount, missed coupons if FCX trades below the barrier, early redemption limiting upside to coupons, product sensitivity to FCX volatility, estimated value below issue price, tax uncertainty, and issuer conflicts of interest.
- Attractive contingent coupon of at least 12.30% annualized, significantly above current short-term rates.
- 31% downside buffer; investors receive full principal if FCX decline remains within this range at maturity.
- Monthly autocalÂl feature may return capital early with coupon if FCX performs well, improving annualized yield.
- Full downside risk: declines beyond �31% convert principal into FCX shares, potentially worthless.
- No participation in upside beyond coupon; gains capped despite equity risk.
- Issuer credit exposure to Citigroup and lack of FDIC/SEC insurance.
- Unlisted security limits liquidity and could trade at substantial discounts before maturity.
- Estimated value below issue price, creating immediate mark-to-market drag.
- Tax treatment uncertain, potentially resulting in higher effective taxes or penalties.
Insights
TL;DR High 12.3% contingent yield and 31% downside buffer offset by full downside risk below barrier, no upside, and Citi credit exposure.
The notes appeal to yield-hunters comfortable with FCX price stability. The 69% barriers provide a moderate cushion; historically FCX has displayed high beta to copper prices, so breaches are plausible. Automatic redemption probability is meaningful if copper rallies; however, that truncates coupon accrual. Investors forfeit any upside beyond coupons, making risk-adjusted return inferior to direct equity for bullish views. Secondary liquidity will be thin, and the issue will price with a 3�5% discount to theoretical value, creating negative carry if sold early.
TL;DR Product’s main risk is principal loss from FCX decline and issuer credit; suits diversified portfolios seeking income with defined barriers.
Citi’s senior unsecured debt is investment-grade (A/A3), but long-dated credit spreads could widen. Because principal is unsecured, a Citi credit event would leave noteholders sharing recovery pari-passu with other senior creditors. The �31% buffer mitigates modest commodity downturns, yet FCX’s historic 52-week volatility (~35-40%) suggests a non-trivial breach probability over 13 months. Tax treatment remains unclear (likely contingent payment swap), exposing investors to audit risk. Overall impact is neutral: product neither materially strengthens nor weakens Citi’s financial profile, but offers retail investors a risk-reward trade-off that warrants cautious sizing.